All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Arkuda Therapeutics, a new company targeting progranulin and lysosomal biology to treat neurodegenerative diseases, has completed a $44 million series A financing led by Atlas Venture, its co-creator, and Pfizer Ventures. Funds managed by Tekla Capital Management LLC and Bioinnovation Capital also participated.
LONDON – It used to be called junk DNA, but now Ervaxx Ltd. has shown the noncoding parts of the genome are a treasure trove of novel cancer antigens. Two years after spinning out of the Francis Crick Institute in London, the company has emerged with a $17.5 million series A funding and a fully formed platform for systematically discovering coding sequences for what it refers to as "dark antigens." (The name is trademarked.)
BEIJING – Antibody developer Akeso Biopharma Inc., from China's Guangdong province, closed a $150 million series D financing round to advance its pipeline, especially the two PD-1-based bispecific antibodies, AK-104 and AK-112, aimed to help it stand out in the fierce PD-1 space in China. "A significant portion of the proceeds will go to AK-104 and AK-112, which are both first-in-class drug candidates," Akeso CEO Michelle Xia told BioWorld. This year is a big one for Akeso, as AK-104 and AK-112 received IND approvals from the FDA in March and July, respectively.
Brisbane-based Kira Biotech Pty Ltd. is poised to enter the clinic after raising AU$20 million (US$13.72 million) in series A funding to develop therapies targeting immune system disorders. The round was led by Oneventures, one of Australia's leading venture capital firms with more than AU$330 million in funds under management.